Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KDM5C | P41229 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23355106 | 0.91 | TSHR (0.35) | TSHRKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL24329788 | 0.90 | TSHR (0.52) | TSHRKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL13340981 | 0.84 | PAOX (0.37) | TSHRKDM4ECA1CA2CA9 | |
| Alethine SCHEMBL689905 | 0.82 | TSHR (0.41) | TSHRCA1CA2CA9LMNA | |
| Cystamine SCHEMBL28779847 | 0.82 | TSHR (0.63) | TSHRKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL18629861 | 0.81 | TSHR (0.43) | TSHRKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL14547392 | 0.81 | CASP2 (0.48) | TSHRTHPOLMNAALDH1A1HDAC3 | |
| SCHEMBL8582768 | 0.80 | TSHR (0.43) | TSHRCA1CA2CA9THPO | |
| SCHEMBL766363 | 0.80 | PHF8 (0.52) | TSHRKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL16549625 | 0.79 | FAAH (0.45) | TSHRCA1CA2CA9THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112672747-B | Peptides for activating cell signaling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2025-02-18 | — | — | CN | disclosed |
| CN-112703185-B | Thiocycloheptyne derivatives and uses thereof | 克里斯特递送有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-03 | — | — | US | disclosed |
| US-20210395216-A1 | THIOCYCLOHEPTYNE DERIVATIVES AND THEIR USE | CRISTAL DELIVERY B.V. (NL) | 2021-12-23 | — | — | US | disclosed |
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3823630-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112703185-A | Thiocycloyne derivatives and uses thereof | 克里斯特递送有限公司 | 2021-04-23 | — | — | CN | disclosed |
| CN-112672747-A | Peptides for activating cell signalling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020013696-A9 | THIOCYCLOHEPTYNE DERIVATIVES AND THEIR USE | CRISTAL DELIVERY B.V. (NL) | 2021-02-25 | — | — | WO | disclosed |
| WO-2020018941-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-23 | — | — | WO | disclosed |
| US-10322180-B2 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | VISION GLOBAL HOLDINGS LTD. (HK) | 2019-06-18 | — | — | US | disclosed |
| EP-3001813-B1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN- BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | VISION GLOBAL HOLDINGS LTD (CN) | 2019-03-27 | — | — | EP | disclosed |
| US-20170266285-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | VISION GLOBAL HOLDINGS LTD. (HK) | 2017-09-21 | — | — | US | disclosed |
| US-9636404-B2 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | VISION GLOBAL HOLDINGS LTD. (CN) | 2017-05-02 | — | — | US | disclosed |
| EP-3001813-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN- BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | Vision Global Holdings Ltd. (CN) | 2016-04-06 | — | — | EP | disclosed |
| WO-2014186301-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN- BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | VISION GLOBAL HOLDINGS LTD. (CN) | 2014-11-20 | — | — | WO | disclosed |
| US-20140335018-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | VISION GLOBAL HOLDINGS LTD. (HK) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395216-A1 | THIOCYCLOHEPTYNE DERIVATIVES AND THEIR USE | CYP7A1, CYP3A5, ABCB1 | TSHR 642/4885KDM4E 3076/4885KDM5C 1197/4885 |
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | ITGB4, ITGA4, ITGB1 | TSHR 1563/4885KDM4E 2319/4885KDM5C 3261/4885 |
| US-10322180-B2 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | HBG2, HBG1, HBB | TSHR 714/4885KDM4E 1846/4885KDM5C 875/4885 |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | ITGB4, ITGA4, ITGB1 | TSHR 1563/4885KDM4E 2319/4885KDM5C 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.